Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS (NCT05379985)

🧪 Interventions in This Study

• RMC-6236 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (21 Sites)

• UC Irvine/Chao Family Comprehensive Cancer Center — Orange, California
• UCLA — Santa Monica, California
• Moffitt Cancer Center — Tampa, Florida
• Piedmont Healthcare — Atlanta, Georgia
• Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
• Johns Hopkins University — Baltimore, Maryland
• Dana Farber Cancer Institute — Boston, Massachusetts
• Perlmutter Cancer Center at NYU Langone Health — New York, New York
• Memorial Sloan-Kettering Cancer Center — New York, New York
• Columbia University — New York, New York
• Christ Hospital Cancer Center — Cincinnati, Ohio
• Taylor Cancer Research Center — Maumee, Ohio
• Tennessee Oncology — Chattanooga, Tennessee
• Sarah Cannon Research Institute — Nashville, Tennessee
• University of Texas at Austin — Austin, Texas
• Mary Crowley Cancer Research — Dallas, Texas
• The University of Texas MD Anderson Cancer Center — Houston, Texas
• Next Oncology — San Antonio, Texas
• Huntsman Cancer Institute — Salt Lake City, Utah
• Next Oncology Virginia — Fairfax, Virginia
• Virginia Mason Medical Center — Seattle, Washington

📞 Contact the Study Coordinator

Phone: (844) 273-8633

Email: medinfo@revmed.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-small Cell Lung Cancer (NSCLC)

• Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) — Oakland, California
• HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer — Santa Monica, California
• PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung — Tampa, Florida
• U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer — Duarte, California
• Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC — Duarte, California
• Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) — Birmingham, Alabama

Explore by condition: All Non-small Cell Lung Cancer (NSCLC) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.